» Articles » PMID: 37493841

Follicular Fluid Composition and Reproductive Outcomes of Women with Polycystic Ovary Syndrome Undergoing in Vitro Fertilization: A Systematic Review

Overview
Publisher Springer
Specialty Endocrinology
Date 2023 Jul 26
PMID 37493841
Authors
Affiliations
Soon will be listed here.
Abstract

Polycystic ovary syndrome (PCOS) is recognized as one of the most prevalent endocrinopathy in women at reproductive age. As affected women tend to have poorer assisted reproductive technology (ART) outcomes, PCOS has been suggested to endanger oocyte quality and competence development. The aim of this systematic review was to summarize the available evidence on how the follicular fluid (FF) profile of women with PCOS undergoing in vitro fertilization (IVF) treatment differs from the FF of normo-ovulatory women. For that, an electronic search in PubMed and Web of Science databases was conducted (up to December 2021). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses - PRISMA guidelines were followed, and the Newcastle-Ottawa Scale was used to assess the risk of bias in the included studies. Data retrieved from papers included (n=42), revealed that the FF composition of women with PCOS compared to those without PCOS predominantly diverged at the following molecular classes: oxidative stress, inflammatory biomarkers, growth factors and hormones. Among those biomarkers, some were proposed as being closely related to pathophysiological processes, strengthening the hypothesis that low-grade inflammation and oxidative stress play a critical role in the pathogenesis of PCOS. Notwithstanding, it should be noticed that the available data on PCOS FF fingerprints derives from a limited number of studies conducted in a relatively small number of subjects. Furthermore, phenotypic heterogeneity of PCOS hampers wider comparisons and weakens putative conclusions. Therefore, future studies should be focused at comparing well characterized patient subgroups according to phenotypes.

Citing Articles

Follicular Fluid Vanin-1 Levels in Patients Undergoing Ivf: A Preliminary Study.

Varnagy A, Mauchart P, Nagy G, Bodis J, Sulyok E Antioxidants (Basel). 2025; 14(2).

PMID: 40002320 PMC: 11851465. DOI: 10.3390/antiox14020133.


The Potential Influence of the Presence of Mycotoxins in Human Follicular Fluid on Reproductive Outcomes.

Szentirmay A, Molnar Z, Plank P, Mezes M, Sajgo A, Martonos A Toxins (Basel). 2024; 16(12.

PMID: 39728767 PMC: 11728479. DOI: 10.3390/toxins16120509.


Unraveling the complexity of follicular fluid: insights into its composition, function, and clinical implications.

Pan Y, Pan C, Zhang C J Ovarian Res. 2024; 17(1):237.

PMID: 39593094 PMC: 11590415. DOI: 10.1186/s13048-024-01551-9.


Follicular Fluid Metabolomics: Tool for Predicting IVF Outcomes of Different Infertility Causes.

Zhang Y, He C, He Y, Zhu Z Reprod Sci. 2024; .

PMID: 39090336 DOI: 10.1007/s43032-024-01664-y.


Anti-Müllerian hormone a surrogate of follicular fluid oxidative stress in polycystic ovary syndrome?.

Vale-Fernandes E, Moreira M, Rodrigues B, Pereira S, Leal C, Barreiro M Front Cell Dev Biol. 2024; 12:1408879.

PMID: 39011395 PMC: 11246868. DOI: 10.3389/fcell.2024.1408879.


References
1.
Yildiz B, Bozdag G, Yapici Z, Esinler I, Yarali H . Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27(10):3067-73. DOI: 10.1093/humrep/des232. View

2.
Balen A, Morley L, Misso M, Franks S, Legro R, Wijeyaratne C . The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016; 22(6):687-708. DOI: 10.1093/humupd/dmw025. View

3.
Escobar-Morreale H . Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018; 14(5):270-284. DOI: 10.1038/nrendo.2018.24. View

4.
Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018; 110(3):364-379. PMC: 6939856. DOI: 10.1016/j.fertnstert.2018.05.004. View

6.
Piomboni P, Focarelli R, Capaldo A, Stendardi A, Cappelli V, Cianci A . Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J Assist Reprod Genet. 2014; 31(10):1269-76. PMC: 4171408. DOI: 10.1007/s10815-014-0307-z. View